Previous studies have suggested that aldosterone is potentially involved in the development of motion sickness and that atrial natriuretic peptide (ANP) may inhibit it. Therefore, the present study was conducted to investigate the inhibitory effects of ANP on aldosterone activity in motion sickness and on aldosterone-induced changes in endolymph volume in the inner ear....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is early-stage mechanistic research in a non-human or basic science context; findings require replication in clinical trials before any implications for vestibular or motion sickness management.
Understanding how inner ear fluid regulation relates to motion sickness could open new pharmacological targets for managing vestibular disorders.
- 01ANP may reduce motion sickness by counteracting aldosterone-driven increases in endolymph (inner ear fluid) volume.
- 02The study investigates a hormonal pathway linking fluid balance and vestibular function.
- 03Published in PLoS ONE, suggesting peer-reviewed but not top-tier vestibular journal placement.
- 04Findings are mechanistic and not yet tested in clinical populations.
- 05Potential relevance to conditions like Ménière's disease where endolymph buildup is a known factor.
Atrial natriuretic peptide (ANP) inhibits motion sickness by reducing aldosterone-induced increases in endolymph volume in the inner ear.
studypartially supportedAldosterone promotes an increase in endolymph volume that contributes to motion sickness.
studypartially supported- PMID
- 42789610
- DOI
- 10.1371/journal.pone.0359426.
- Journal
- PLoS ONE
- Publication type
- research_article
- Evidence level
- 4
- Population
- Not specified — likely animal or in-vitro model investigating inner ear fluid dynamics
- Intervention
- Atrial natriuretic peptide (ANP) administration
- Comparator
- Aldosterone-induced endolymph volume increase (control condition)
Primary outcomes
Endolymph volume change in the inner ear; Motion sickness inhibition